Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Amphastar Pharmaceuticals Cash Flow from Operating Activities 2012-2024 | AMPH

Amphastar Pharmaceuticals cash flow from operating activities from 2012 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
  
Amphastar Pharmaceuticals Annual Cash Flow Ops
(Millions of US $)
2023 $184
2022 $89
2021 $98
2020 $57
2019 $42
2018 $38
2017 $39
2016 $39
2015 $11
2014 $21
2013 $31
2012 $-2
2011 $19
2009 $
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.072B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $18.924B 6.59
Dr Reddy's Laboratories (RDY) India $11.661B 17.34
Aspen Pharmacare (APNHY) South Africa $5.609B 0.00
BridgeBio Pharma (BBIO) United States $5.333B 0.00
Bausch Health Cos (BHC) Canada $2.615B 1.99
Supernus Pharmaceuticals (SUPN) United States $1.632B 0.00
Taysha Gene Therapies (TSHA) United States $0.449B 0.00
Generation Bio (GBIO) United States $0.189B 0.00
Personalis (PSNL) United States $0.080B 0.00
Assembly Biosciences (ASMB) United States $0.074B 0.00
Acasti Pharma (ACST) Canada $0.026B 0.00
Sol-Gel Technologies (SLGL) Israel $0.019B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00